BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

PharmAbcine Announces Last Patient Last Visit in its Phase Ib mTNBC Combination Trial

The clinical study, which had the first patient dosed in December 2018, evaluated the safety and clinical efficacy of olinvacimab, the Company's anti-...

February 28, 2022 | News

CanSinoBIO's Convidecia™ Approved as Heterologous Booster in China

According to the State Council, for those aged 18 and above who have completed a 6-month vaccination schedule using inactivated COVID-19 vaccines, and thos...

February 21, 2022 | News

Quotient Sciences completes integration of drug substance into translational pharmaceutics® platform

Quotient Sciences – a global drug development and manufacturing accelerator offering a suite of services to clients in the pharmaceutical and bi...

February 18, 2022 | News

Biotium announces optimised antibody labeling kits for super-resolution microscopy

Biotium, a supplier of cutting-edge life science reagents, is expanding their line of industry-leading Mix-n-Stain™ labeling kits with new kits desig...

February 16, 2022 | News

Kintor Pharma Announces First Patient Dosing in China

Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological th...

February 14, 2022 | News

GenScript Sets Up State-Of-Art Manufacturing Facility in Singapore to Strengthen Manufacturing Capability

The state-of-the-art site marks a significant expansion of the company's advanced protein and gene platforms, and is designed to provide high quality...

February 10, 2022 | News

LISCure Biosciences Announces Research Collaboration with The Scripps Research Institute for Immuno-Oncology

Scripps Research is the top nonprofit scientific institute in the US for producing high-quality research based on discoveries published in leading scientif...

February 04, 2022 | News

Clarity advances to cohort 2 in the SARTATE™ neuroblastoma trial

No dose limiting toxicities (DLTs) have been reported in cohort 1 - The Safety Review Committee (SRC) has recommended the trial continues with the d...

February 02, 2022 | News

Debiopharm and Aspen Partner to launch prostate cancer drug trelstar® in South Africa

In 2020, nearly 14,000 South African men were newly diagnosed with prostate cancer1 with an average of 5 men dying from the disease every day.2 I...

February 01, 2022 | News

ImmVira's New-Generation Vector Poised to Enable CAR-T Treatment for Solid Tumors

Solid tumor has long been a challenge for CAR-T. Major obstacles include solid tumor heterogeneity, lack of tumor associated antigens as CAR-T targets, com...

January 25, 2022 | News

The Philippines Has Approved ReCOV For Phase II/III Clinical Trial

Recombinant Two-Component COVID-19 Vaccine (ReCOV) was approved for International Phase II/III Clinical Trial ReCOV induced high levels of neutralizing ...

January 18, 2022 | News

China Based Gracell Biotechnologies Unveils Innovation Center in U.S.

As a pivotal part of Gracell's global strategy, the company is fully committed to expanding its operations in the U.S. to enhance and diversify its in-hous...

January 13, 2022 | News

Clario and XingImaging expand partnership to deliver PET imaging clinical trials in China

Clario, formerly ERT and Bioclinica, and XingImaging joined forces in 2018 to support multi-center clinical trials requiring PET for eligibility and drug e...

January 12, 2022 | News

CARsgen Announces CT041 CAR T-cell Product Candidate Granted RMAT Designation by the FDA

With the RMAT designation, CT041 enjoys all the benefits of Fast Track and Breakthrough Therapy designations including early and intensive FDA guidance on ...

January 11, 2022 | News

Stay Connected